ACT-385781A (Actelion Epoprostenol) ( DrugBank: Epoprostenol )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	2

86. 肺動脈性肺高血圧症

---

臨床試験数 : 1,205 /  薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01105117 (ClinicalTrials.gov)	May 2010	15/4/2010	Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401	An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH)	Pulmonary Arterial Hypertension	Drug: ACT-385781A (Actelion Epoprostenol);Drug: Flolan®	Actelion	NULL	Completed	18 Years	65 Years	All	2	Phase 4	United States
2	NCT01105091 (ClinicalTrials.gov)	March 2010	15/4/2010	Epoprostenol for Injection in Pulmonary Arterial Hypertension	A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokinetics of ACT- 385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH)	Pulmonary Arterial Hypertension	Drug: ACT-385781A (Actelion Epoprostenol);Drug: Flolan®	Actelion	NULL	Completed	18 Years	65 Years	All	30	Phase 4	United States